| | To ensure that you never miss an issue, please whitelist us. |
|
|
| | | Bromocriptine-QR (Cycloset) “is a sympatholytic dopamine D2 agonist for the treatment of type 2 diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse cardiovascular events in this population by as yet incompletely delineated mechanisms.” This study investigated the impact of Cycloset on the pro-inflammatory state of type 2 diabetes subjects as it relates to CVD. |
|
|
Researchers characterized trends and disparities in glycemic control and severe hyperglycemia in U.S. adults with diabetes using insulin in a serial population-based cross-sectional study using data from the National Health and Nutrition Examination Survey between 1988 to 1994 and 1999 to 2020. Data were included for 2,482 participants with diabetes using insulin. |
| | |
| |
| |
Colleagues examined whether metformin use is associated with a reduced risk for TKR or THR among patients with type 2 diabetes. Data were included for 20,347 participants who were not treated with metformin and 20,347 who were treated with metformin after prescription-time distribution matching. |
| | |
|
|
|
